修美乐-话题@MedSci

#修美乐#

16篇内容 | 664人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1619931, encodeId=b17c1619931ba, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=艾伯维指控Alvotech窃取修美乐商业机密, objectType=article, longId=209489, objectId=a3022094894b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3022094894b, replyNumber=0, likeNumber=35, createdTime=2021-04-05, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3022094894b, moduleTitle=艾伯维指控Alvotech窃取修美乐商业机密, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3022094894b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619930, encodeId=b5d216199304c, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=40, createdTime=2020-11-04, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619929, encodeId=e5d41619929d9, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=修美乐第二个国产仿制药获批在即, objectType=article, longId=184177, objectId=68071841e724, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68071841e724, replyNumber=0, likeNumber=39, createdTime=2019-12-06, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68071841e724, moduleTitle=修美乐第二个国产仿制药获批在即, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68071841e724)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619928, encodeId=c6f8161992830, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=修美乐国产首仿获批在即, objectType=article, longId=181969, objectId=c694181969c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c694181969c3, replyNumber=0, likeNumber=40, createdTime=2019-10-27, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c694181969c3, moduleTitle=修美乐国产首仿获批在即, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c694181969c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619927, encodeId=5d96161992e78, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=修美乐、格列卫等再降价, objectType=article, longId=178991, objectId=b4d71e899192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4d71e899192, replyNumber=0, likeNumber=45, createdTime=2019-09-07, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4d71e899192, moduleTitle=修美乐、格列卫等再降价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4d71e899192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619926, encodeId=56051619926e6, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, objectType=article, longId=178540, objectId=b7281e8540c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7281e8540c0, replyNumber=0, likeNumber=40, createdTime=2019-09-03, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7281e8540c0, moduleTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7281e8540c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619925, encodeId=e53f16199259c, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, objectType=article, longId=162132, objectId=47be16213263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47be16213263, replyNumber=0, likeNumber=22, createdTime=2019-03-13, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47be16213263, moduleTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47be16213263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619924, encodeId=0c991619924f1, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半, objectType=article, longId=159001, objectId=47a61590015d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47a61590015d, replyNumber=0, likeNumber=46, createdTime=2019-01-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47a61590015d, moduleTitle=年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47a61590015d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619923, encodeId=588116199238b, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=药王修美乐生物类似物开卖，欧洲降价8成, objectType=article, longId=152648, objectId=421c1526484f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=421c1526484f, replyNumber=0, likeNumber=33, createdTime=2018-11-04, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=421c1526484f, moduleTitle=药王修美乐生物类似物开卖，欧洲降价8成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=421c1526484f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619922, encodeId=3d6b1619922c7, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=Ann Rheum Dis：阿达木单抗生物类似物BI 695501和修美乐对中重度活动性类风湿性关节炎具有相似疗效、安全性和免疫原性, objectType=article, longId=136088, objectId=8b931360884f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b931360884f, replyNumber=0, likeNumber=35, createdTime=2018-04-23, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b931360884f, moduleTitle=Ann Rheum Dis：阿达木单抗生物类似物BI 695501和修美乐对中重度活动性类风湿性关节炎具有相似疗效、安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b931360884f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619921, encodeId=6597161992113, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, objectType=article, longId=112593, objectId=1db4112593da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1db4112593da, replyNumber=0, likeNumber=0, createdTime=2017-09-13, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1db4112593da, moduleTitle=勃林格殷格翰的修美乐生物类似药获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1db4112593da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619920, encodeId=f61816199206d, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, objectType=article, longId=101021, objectId=091a10102187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091a10102187, replyNumber=0, likeNumber=33, createdTime=2017-06-09, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091a10102187, moduleTitle=艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091a10102187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619919, encodeId=44ba1619919e6, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎, objectType=article, longId=69400, objectId=f315694009f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f315694009f, replyNumber=0, likeNumber=41, createdTime=2016-05-30, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f315694009f, moduleTitle=艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f315694009f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619918, encodeId=a84f1619918ea, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=英国NICE推荐修美乐（Humira）治疗化脓性汗腺炎, objectType=article, longId=67904, objectId=8d336e904f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d336e904f2, replyNumber=0, likeNumber=28, createdTime=2016-05-12, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d336e904f2, moduleTitle=英国NICE推荐修美乐（Humira）治疗化脓性汗腺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d336e904f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619917, encodeId=ea55161991e93, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=中国的“修美乐”何时才能面世？, objectType=article, longId=36075, objectId=1b75360e504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b75360e504, replyNumber=0, likeNumber=31, createdTime=2014-06-07, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b75360e504, moduleTitle=中国的“修美乐”何时才能面世？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b75360e504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1619916, encodeId=6ad6161991678, content=<a href='/topic/show?id=b6782e416ef' target=_blank style='color:#2F92EE;'>#修美乐#</a>, objectTitle=依那西普与修美乐仍是美国RA一线生物治疗药物的“中流砥柱”, objectType=article, longId=25176, objectId=837e251e6c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e251e6c0, replyNumber=0, likeNumber=26, createdTime=2013-10-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e251e6c0, moduleTitle=依那西普与修美乐仍是美国RA一线生物治疗药物的“中流砥柱”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=837e251e6c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

修美乐

2020-05-29

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

艾伯维指控Alvotech窃取修美乐商业机密

2021-04-05

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2020-11-04

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

修美乐第二个国产仿制药获批在即

2019-12-06

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

修美乐国产首仿获批在即

2019-10-27

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

修美乐、格列卫等再降价

2019-09-07

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当

2019-09-03

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐

2019-03-13

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

年销售额达180亿美元的修美乐将失去市场专属权，仿制药预计一年内占据市场的一半

2019-01-28

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

药王修美乐生物类似物开卖，欧洲降价8成

2018-11-04

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

Ann Rheum Dis：阿达木单抗生物类似物BI 695501和修美乐对中重度活动性类风湿性关节炎具有相似疗效、安全性和免疫原性

2018-04-23

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

勃林格殷格翰的修美乐生物类似药获FDA批准

2017-09-13

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

艾伯维产品修美乐在华获批用于治疗中重度斑块型银屑病

2017-06-09

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

艾伯维旗舰产品修美乐（Humira）获欧盟CHMP支持批准，治疗非感染性葡萄膜炎

2016-05-30

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

英国NICE推荐修美乐（Humira）治疗化脓性汗腺炎

2016-05-12

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

中国的“修美乐”何时才能面世？

2014-06-07

docwu2019 (审核中...)

前往app查看评论内容

#修美乐#

依那西普与修美乐仍是美国RA一线生物治疗药物的“中流砥柱”

2013-10-02

科室
- - 订阅+
  - 更多科室
工具
服务